Des drogues sur mesure: un nouveau problème de sécurité au travail
Cette étude se concentre sur les cannabinoïdes synthétiques, le contexte épidémiologique des dernières drogues disponibles en Europe et la présence de ces nouvelles drogues chez les conducteurs. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.
Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.
Drink driving has been on the enforcement radar for over 40 years and the dangers of drug driving are well recognised, yet there’s a rising new face on impaired driving - designer drugs.
Many organisations already have alcohol and other drug screening programs that test employees’ urine and oral fluid to evaluate whether they can safely perform at work. Yet new designer drugs are arriving at an unprecedented rate, and are much more difficult to detect, presenting a constant challenge for drug monitoring programs.
A special session entitled Designer drugs: The new face of drug abuse, being held in conjunction with the T2013 Conference later this year, will profile synthetic cannabinoids as the new face of drug abuse, investigate the epidemiological background on the latest new drugs in Europe, present case studies on driver intoxication, and unveil new ways for screening and confirmation of the presence of these new drugs in drugged drivers.
Detection of the latest designer drugs can be a tricky business. Register for T2013 to hear more at www.t2013.com
T2013: the 20th Conference of the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) will bring over 400 workplace health and safety managers, researchers, stakeholders and practitioners together from 25-28 August in Brisbane to discuss the latest in research, international programs, policy and development in impaired driving.
The full conference program will be available shortly and earlybird registration closes on 24 May. Visit www.t2013.com to register or to keep abreast of conference updates.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.